Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Rocket Lab USA Inc (RKLB) Price & Performance

Eli Lilly And CoTrade
Rocket Lab USA IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Rocket Lab USA Inc — how do they compare? Eli Lilly And Co trades at $1,220.55 (market cap $1.08T), while Rocket Lab USA Inc trades at $81.15 (market cap $50.01B). The key difference: Eli Lilly And Co is far larger — about 21.6× Rocket Lab USA Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.

LLYRKLB
Market Cap
$1.08T$50.01B
Sector
HealthTechnology
52-Week High
$1.24K$150.23
52-Week Low
$639.43$39.48
Enterprise Value
$1.13T$47.84B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Rocket Lab USA Inc

Rocket Lab (RKLB) trades at $81.30, up 1.57% in the last session, with a bullish technical outlook and strong analyst support. The stock is near its pivot point of $79, with resistance at $82. Fundamentally, revenue grew 62% year-over-year in Q2 2026 to a record $601.80 million, but the company remains unprofitable with a net income margin of -26.87%. Recent news highlights the Neutron rocket's upcoming launch and a $2.36 billion backlog, though margin pressures and cash burn are concerns.

The outlook is mixed: analysts project 76% buy ratings and a $118.00 price target, signaling confidence in growth from launch demand and contracts. However, high valuation (P/S of 60.8), persistent losses, and execution risks around Neutron's timeline pose significant downside. Investors should weigh growth potential against profitability challenges and competitive pressures in the space sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Rocket Lab USA Inc

Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.

Read more on RKLB